Environmental impact of inhalers - average carbon footprint per salbutamol inhaler by all Sub-ICB Locations

Why it matters: The NHS has committed to reducing its carbon footprint by 80% by 2028 to 2032, including a shift to lower carbon inhalers.

Salbutamol metered dose inhalers (MDIs) are the single biggest source of carbon emissions from NHS medicines prescribing. The 2022-2023 PCN Investment and Impact Fund (IIF) therefore includes an indicator focusing on mean carbon emissions per salbutamol inhaler prescribed (kg CO2e). The aim is to encourage prescribing of salbutamol products associated with lower carbon emissions, resulting in a significant reduction in NHS carbon emissions.

Data on carbon emissions per salbutamol inhaler can be viewed in the table here.

Description: Mean carbon impact (kg CO2e) per salbutamol inhaler prescribed


Tagged as: Standard, Greener NHS, NHS England Investment and Impact Fund, Respiratory (or browse all measures)

Sub-ICB Locations are ordered by mean percentile over the past six months. Each chart shows the results for the individual Sub-ICB Location, plus deciles across all Sub-ICB Locations in the NHS in England.

View measure for NHS England combined →

Fetching data...

Do you need help with your analysis? Don't forget to check the FAQ page, and if you have questions.